Zevra Pharmaceuticals is showcasing AZSTARYS at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
AZSTARYS's Schedule IV classification is its key differentiator in a stimulant-wary environment. At APA, where psychiatrists are increasingly cautious about stimulant prescribing (abuse potential, diversion), Schedule IV messaging resonates. Collegium Pharma acquisition ($650M) closing Q2 2026 creates transition context.
Ask about: Schedule IV real-world abuse/diversion data; how the Collegium acquisition affects commercial strategy; prescriber comfort level with Schedule IV classification; competitive positioning vs. Schedule II stimulants and non-stimulants (Qelbree, solriamfetol). Transition period = potential for new partner conversations.
ePRO+ captures adherence patterns and can document the absence of abuse/misuse signals — generating the real-world evidence that supports the Schedule IV claim. VoiceVitals for ADHD symptom monitoring.
Set up a follow-up with Zevra Pharmaceuticals's team and Videra Health.
Email Ryan Roberts →